Healthcare Sales & Marketing Network News: interferon

Searching News Database: interferon

HSMN NewsFeed - 14 Dec 2022
STORM Therapeutics announces closing of USD $30M Series B financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Sep 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Apr 2022
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Feb 2022
Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch

HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Mar 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Sep 2019
Novo Seeds Co-leads €20 Million Series A Financing in STipe Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 30 Sep 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Aug 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jul 2019
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Jun 2019
Sobi Acquires Emapalumab and Related Assets
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 10 Jun 2019
Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Biopharmaceuticals Litigation Licensing

HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 26 Mar 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA

HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Jan 2018
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jan 2018
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 29 Nov 2017
Frazier-backed Mavupharma secures $20M in Series A financing to fund STING program
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 5 Sep 2017
Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Sep 2017
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Aug 2017
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 27 Jul 2017
Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jun 2017
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 14 Jun 2017
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2017
QIAGEN's QuantiFERON(R)-TB Gold Plus gains U.S. FDA approval
Diagnostics FDA

HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 18 Apr 2017
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
Biopharmaceuticals Gastroenterology Surgery Personnel

HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Mar 2017
Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jan 2017
Ascletis Raises US$100 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology

HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory

HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch

HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 May 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Biopharmaceuticals Licensing Acquisitions

HSMN NewsFeed - 3 May 2016
Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Apr 2016
BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 20 Jan 2016
Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection(R) as a Treatment of Middle East Respiratory Syndrome (MERS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Sep 2015
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Sep 2015
Ascletis Secures US$35 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Jan 2015
Debiopharm Group(TM) Regains Full Rights to Alisporivir Program
Biopharmaceuticals

HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Aug 2014
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Aug 2014
Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jun 2014
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza(R) (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Jun 2014
Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2014
Gilead’s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals

HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 19 Mar 2014
Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma plc
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Jan 2014
European Commission Grants Marketing Authorization for Gilead’s Sovaldi(R) (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals

HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2013
Vertex Sells INCIVO(R) Product Royalty Rights for $152 Million
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Oct 2013
Nuron Biotech Announces Appointment of New Management Team Members and Provides an Update on Commercial Vaccine Meningitec(TM)
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 21 May 2013
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY(TM) (Peginterferon Beta-1a) in Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 15 May 2013
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Feb 2013
Helix BioPharma Announces Director Resignation
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jan 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Dec 2012
Helix BioPharma Announces Director Resignations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Dec 2012
Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec(TM) from Pfizer
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 1 Nov 2012
Resolve Therapeutics Raises $5.8 Million in Private Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2012
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jun 2012
Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA(TM) (alemtuzumab) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA Regulatory

HSMN NewsFeed - 1 Jun 2012
Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIO(TM)* (teriflunomide) in Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 May 2012
Achillion Announces Executive Promotion
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2012
TONIX Pharmaceuticals Strengthens Management Team with the Appointments of Its New Chief Financial Officer and Senior Director of Drug Development
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 28 Feb 2012
FDA Approves AVONEX(R) PEN(TM) and Dose Titration Regimen
Biopharmaceuticals Drug Delivery Neurology FDA

HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Oct 2011
Anadys Announces Agreement To Be Acquired By Roche
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Jun 2011
Biogen Idec Receives Approval in the European Union for AVONEX(R) PEN(TM)
Biopharmaceuticals Drug Delivery Neurology Regulatory

HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 May 2011
EMD Serono President and CEO Fereydoun Firouz Resigns
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 May 2011
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 18 May 2011
Abbott Receives FDA Approval for Molecular Test for Hepatitis C
Diagnostics FDA

HSMN NewsFeed - 17 May 2011
Resolve Announces Series A Financing, New Board Members
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals

HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2011
Important Information for Betaseron (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products
Biopharmaceuticals Devices Product Recall

HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Nov 2010
OctoPlus Appoints Jan Hendrik Egberts as CEO
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 25 Oct 2010
Kadmon Pharmaceuticals Acquires Three Rivers Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 7 Sep 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Sep 2010
Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Aug 2010
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jul 2010
Three Rivers Pharmaceuticals Announces FDA Approval Of Expanded Labeling of INFERGEN
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jul 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jun 2010
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Biopharmaceuticals Neurology

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2010
Human Genome Sciences Announces Withdrawal of European Marketing Authorization Application For JOULFERON(R) (ZALBIN) For the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Mar 2010
Human Genome Sciences Appoints David P. Southwell Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Feb 2010
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jan 2010
Two-Year Results From CLARITY Study with Cladribine Tablets in Multiple Sclerosis Published in The New England Journal of Medicine
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Jan 2010
GlobeImmune Announces $17.5 Million Series E Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Sep 2009
BurnsAdler Partners With Three Rivers Pharmaceuticals to Commercialize Infergen(R) in Brazil and Chile
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jul 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 8 Jul 2009
Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 10 Jun 2009
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 May 2009
Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 May 2009
Merck Serono Launches Glucophage Powder in First European Countries
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 29 Apr 2009
New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Apr 2009
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 21 Apr 2009
Merck Serono Launches Kuvan(R) in Europe
Biopharmaceuticals

HSMN NewsFeed - 20 Apr 2009
Newly Published Study Shows That Re-Treatment With Pegasys(R) (Peginterferon Alfa-2a) Provides Hepatitis C Patients With a Second Chance for a Cure
Biopharmaceuticals

HSMN NewsFeed - 23 Mar 2009
Merck Serono Launches Strategic Venture Capital Fund
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2009
Aethlon Medical Announces Significant Viral Load Reduction in Landmark Medical Device Study to Treat HIV/AIDS
Devices HIV/AIDS

HSMN NewsFeed - 9 Mar 2009
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Feb 2009
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Biopharmaceuticals Licensing

HSMN NewsFeed - 3 Feb 2009
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals

HSMN NewsFeed - 13 Jan 2009
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 4 Dec 2008
European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 3 Nov 2008
Biolex Therapeutics Adds Two Drug Development Executives to Accelerate Development of Locteron(R) in Hepatitis C
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Oct 2008
EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
Biopharmaceuticals Licensing

HSMN NewsFeed - 6 Oct 2008
Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron(R) Commercial Rights
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2008
Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron(R) in Hepatitis C
Biopharmaceuticasl Venture Capital

HSMN NewsFeed - 22 Sep 2008
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Sep 2008
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Sep 2008
Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) from Amgen Inc.
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 Sep 2008
Teva Receives EU Marketing Authorization for TevaGrastim(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Sep 2008
Betaseron(R) to Offer the Thinnest Needle in Multiple Sclerosis
Biopharmaceuticals Drug Delivery Neurology

HSMN NewsFeed - 27 Aug 2008
Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jun 2008
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Jun 2008
Merck Serono's Rebif(R) Celebrates 10th Anniversary
BIopharmaceuticals Neurology

HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals

HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2008
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Apr 2008
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Apr 2008
VioQuest Pharmaceuticals Names Vernon L. Alvarez, Ph.D. as Vice President, Research & Development and Announces Resignation of Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Apr 2008
COPAXONE(R) Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression in Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Mar 2008
Presidio Pharmaceuticals Obtains Exclusive Worldwide Rights to XTL Biopharmaceuticals Ltd. Hepatitis C Virus (HCV) NS5A Program
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Mar 2008
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Biopharmaceuticals Litigation

HSMN NewsFeed - 13 Mar 2008
Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Mar 2008
Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2008
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jan 2008
Carol L. Brosgart, M.D., Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jan 2008
Teva to Acquire CoGenesys
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Jan 2008
Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Devices Drug Delivery Oncology Personnel

HSMN NewsFeed - 26 Dec 2007
Cubist Pharmaceuticals Acquires Illumigen Biosciences
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Dec 2007
Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 20 Dec 2007
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Biopharmaceuticals Licensing

HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine

HSMN NewsFeed - 26 Nov 2007
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Nov 2007
Maxygen Updates Status of MAXY-alpha Program
Biopharmaceuticals

HSMN NewsFeed - 15 Nov 2007
Helix BioPharma Corp. announces management changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2007
Allozyne, Inc., Closes $30 Million Series B Financing and Appoints Meenu Chhabra as President and Chief Executive Officer
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Oct 2007
Study Showed Patients Using COPAXONE(R) Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif(R) in Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Oct 2007
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Oct 2007
COPAXONE(R) Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (IFNb) Due to Development of Neutralizing Antibodies (NAbs)
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Oct 2007
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Aug 2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
Biopharmaceuticals Licensing

HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Aug 2007
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Biopharmaceuticals

HSMN NewsFeed - 1 Aug 2007
NCCN Updates Kidney Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 2 Jul 2007
ZymoGenetics Announces Senior Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jun 2007
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2007
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
Pivotal Phase III Trial Showed PROMACTA(R) (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jun 2007
Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon(R)
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2007
Lewis T. 'Rusty' Williams, M.D., Ph.D. Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA

HSMN NewsFeed - 21 May 2007
PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2007
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
Biopharmaceuticals

HSMN NewsFeed - 14 May 2007
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 May 2007
Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron(R)
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 May 2007
Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C Research and Behcet's Disease and Oral Warts Phase 2 Trials
Biopharmaceuticals

HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 May 2007
First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron(R) Significantly Delayed Permanent Disability
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 25 Apr 2007
OctoPlus Gains Full Rights to PolyActive Drug Delivery Technology From IsoTis
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 23 Apr 2007
Hemispherx and Armada Health Care enter Agreement to Launch Alferon N Injection(R) via Specialty Pharmacy Network
Biopharmaceuticals

HSMN NewsFeed - 18 Apr 2007
Viragen Announces European Multiferon(R) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 13 Apr 2007
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals

HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 6 Apr 2007
Wyeth Provides Update on FDA Review of the Torisel New Drug Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Mar 2007
Respironics' I-neb(R) Device Utilized in Clinical Evaluation Of Interferon Gamma in Idiopathic Pulmonary Fibrosis Patients
Devices

HSMN NewsFeed - 14 Mar 2007
Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study
Biopharmaceuticals

HSMN NewsFeed - 12 Mar 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 Mar 2007
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Feb 2007
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Jan 2007
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Jan 2007
Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2007
Presidio Pharmaceuticals Receives Exclusive License to Novel Hepatitis C Virus (HCV) Technology from Stanford University
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Jan 2007
Roche Diagnostics Submits Hepatitis C Viral Load Monitoring Test to FDA
Diagnostics FDA

HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology

HSMN NewsFeed - 8 Jan 2007
Juvaris Announces First Round Closing of Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Jan 2007
Nektar Appoints Howard W. Robin President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals

HSMN NewsFeed - 3 Jan 2007
CoGenesys Files to Begin Clinical Trials of Neugranin for the Prevention of Infections in Cancer Patients
Biopharmaceuticals

HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals

HSMN NewsFeed - 22 Dec 2006
Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change
Biopharmaceuticals Acquisitions Personnel

HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Dec 2006
FDA Grants Torisel NDA Priority Review Status
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Dec 2006
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 15 Dec 2006
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 14 Dec 2006
Jenken Biosciences Receives FDA Clearance for Phase II Trial of Lead Compound
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals

HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals

HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2006
Hemispherx Biopharma Hires New President/Chief Operating Officer to Lead the Company's Drive to Commercialization
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Nov 2006
Biota and Boehringer Ingelheim Complete US$102 Million License for HCV Program
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Nov 2006
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology

HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 31 Oct 2006
Human Genome Sciences Reports Positive Interim Results of Phase 2 Trials of Albuferon(TM) With Ribavirin in Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Idenix Announces New 24-Week Data From A Phase IIb Clinical Trial Of Valopicitabine Plus Pegylated Interferon in Treatment Naive Genotype-1 Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients in Early Trial
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 24 Oct 2006
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 23 Oct 2006
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Oct 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for Albuferon(TM) in Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2006
New Data Reinforce Efficacy of TRIZIVIR(R) Alone in Treatment-Naive HIV Patients with Low Viral Load
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2006
One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Sep 2006
Acorda Therapeutics Announces Positive Results of Phase 3 Study of Fampridine-SR on Walking in People with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Sep 2006
Valeant Pharmaceuticals Reports VISER2 Results for Viramidine(R)
Biopharmaceuticals

HSMN NewsFeed - 7 Sep 2006
Omeros Acquires Nura
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Jul 2006
CoGenesys Receives FDA Clearance to Commence Clinical Trials of Cardeva in Patients with Chronic Heart Failure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 11 Jul 2006
New Autoinjection Device Designed to Work With Betaseron(R) Now Available For Patients With Multiple Sclerosis
Biopharmaceuticals Devices Neurology Drug Delivery

HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 30 Jun 2006
Jonathan R. Spicehandler, M.D. Retires From Schering-Plough
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jun 2006
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology

HSMN NewsFeed - 31 May 2006
COPAXONE(R) Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When Avonex(R) Failed
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 May 2006
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 19 May 2006
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 386

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 386 additional stories matching:
interferon
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.